Guardant Health, Inc. GH
145.59 USD +0.45 (+0.31%)
Regular-session close
145.59 0.00 0.00%
After hours · Nov 19, 4:00 PM ET
145.47 Day range 155.97
74.55 52-week range 191.05
- YTD
- +42.54%
- 1 year
- +46.25%
News
businesswire.com Guardant Health Launches Guardant Reveal® Ultra to Deliver Leading Sensitivity in MRD Testing PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the U.S. clinical launch of Guardant Reveal® Ultra, a new molecular…
businesswire.com Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on October 13, 2026, the Compensation Committee of Guardant's Board…benzinga.com Piper Sandler Maintains Overweight on Guardant Health, Lowers Price Target to $190 Piper Sandler analyst David Westenberg maintains Guardant Health (NASDAQ:GH) with a Overweight and lowers the price target from $193 to $190.
benzinga.com Guardant Health Q3 2026 Earnings Call Transcript Guardant Health (NASDAQ:GH) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…benzinga.com Guardant Health Raises FY2026 Sales Guidance from $1.340B-$1.360B to $1.360B-$1.370B vs $1.357B Est Guardant Health (NASDAQ:GH) raises FY2026 sales outlook from $1.340 billion-$1.360 billion to $1.360 billion-$1.370 billion vs $1.357 billion estimate.
benzinga.com Guardant Health Q3 Adj. EPS $(0.29) Beats $(0.32) Estimate, Sales $360.975M Beat $350.358M Estimate Guardant Health (NASDAQ:GH) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.32) by 9.38 percent. This is a 25.64 percent increase over losses of…
benzinga.com TwinStrand Biosciences Announces Confirmation Of U.S. Patent And Trademark Office Regarding Patentability Of All 23 Claims Of U.S. Patent Against Guardant Health TwinStrand Biosciences (TwinStrand), the pioneer in Duplex Sequencing technology, today announced that the U.S. Patent and Trademark Office (USPTO) has confirmed the patentability of all 23 claims of…
benzinga.com BTIG Maintains Buy on Guardant Health, Raises Price Target to $210 BTIG analyst Mark Massaro maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $195 to $210.
benzinga.com This Guardant Health Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday Analysts initiated coverage: VSE Sector Weight; Guardant, Quantum, Benitec and Diodes rated Buy/Overweight/Outperform with targets up to $200.benzinga.com Roth Capital Initiates Coverage On Guardant Health with Buy Rating, Announces Price Target of $200 Roth Capital analyst Max Masucci initiates coverage on Guardant Health (NASDAQ:GH) with a Buy rating and announces Price Target of $200.
